In a recent study published in the Journal of Psychopharmacology, we were able to share the results of our SOFIA protocol used for children with Attention Deficit Hyperactivity Disorder (ADHD). SOFIA was created for children with ADHD to deliver reminders and educational messages in order to improve adherence and management of ADHD. ADHD is a neurobehavioral disorder that impacts approximately 11% of children […]
Looking back on MEMOTEXT’s accomplishments this fall
Posted on December 2, 2015 by Noah Nemoy
This autumn has been an exciting time for MEMOTEXT. In September our Founder and President Amos Adler had the opportunity to be a main stage speaker at Stanford Medicine X 2015. Presenting the abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” Amos rocked the crowd explaining the MEMOTEXT methodology. He had a fantastic time at the event and the “Cat pics + health data = behavior change” line got a substantial amount of press coverage.
Posted on November 05, 2015 by Noah Nemoy
Medication Compliance is one of the biggest costs to worldwide healthcare systems. 50% of all patients do not take their medication as prescribed and this costs the U.S. healthcare system alone $290 billion per year. That’s a pretty massive figure that can be interpreted in several ways.
We can start by breaking down that $290 billion to show exactly how low compliance rates create such a huge cost:
Posted on July 6, 2015 by Noah Nemoy
Last week, MEMOTEXT Founder and President Amos Adler was invited to both attend and present at the 14th Annual Patient Adherence & Access Summit, or PAAS2015 in Philadelphia. While there MEMOTEXT had the opportunity to share in the discussion of the latest issues regarding patient adherence and access, to medication.
Director of Scientific Development Bill Simpson unveils our new BAM adherence metric
Posted on June 26, 2015 by Bill Simpson
2 weeks ago MEMOTEXT had the privilege of presenting our new Balanced Adherence Metric (BAM) at the inaugural Science of Medication Adherence Conference (SMA2015), hosted by the University of Pittsburgh Centre for Pharmaceutical Policy and Prescribing.
MEMOTEXT to present at both Washington D.C.’s Health Datapalooza 2015 and Pittsburgh’s SMA 2015 this week
Washington, D.C. June 1, 2015 – MEMOTEXT Corp. announces today the upcoming presentation of the Balanced Adherence Metric (BAM). The BAM will be presented tomorrow by MEMOTEXT’s Director of Scientific Development Bill Simpson, Ph.D. Candidate in Neuroscience, at the inaugural Science of Medication Adherence conference (SMA 2015) at the University of Pittsburgh. MEMOTEXT also has a delegation at Washington D.C.’s Health Datapalooza 2015 including Founder and President of MEMOTEXT Amos Adler, M.Sc. Health Datapalooza 2015 runs from today until Wednesday and MEMOTEXT will be present for the entire duration.
MEMOTEXT Validates the Balanced Adherence Metric (BAM)
Posted on May 28, 2015 by Noah Nemoy
Finding ways to accurately measure medication adherence can be difficult. Currently, most metrics use pharmacy claims data to measure an individual’s adherence. Many academics and professionals use measures like Proportion of Days Covered (PDC) or Medication Possession Ratio (MPR). But while these measures have several advantages, they don’t account for other adherence factors, such as delay to refill and medication persistence. To solve the problem, MEMOTEXT developed the Balanced Adherence Metric (BAM). BAM amalgamates the four most common adherence measures, providing a more accurate and holistic metric.
Updated on April 6, 2015 by Noah Nemoy
MEMOTEXT is honored that our patient adherence solutions have been selected as a finalist for the 3rd Annual Scattergood Foundation Innovation Award! This prestigious award recognizes innovation breakthroughs in the field of behavioral health-care.
Posted on March 11, 2015 by Noah Nemoy
This March 8-15, is World Glaucoma Week. Launched 6 years ago by the World Glaucoma Association and The World Glaucoma Patient Association, events are being held across the world to raise awareness about Glaucoma. Afflicting 9 million people, Glaucoma is the world’s leading cause of irreversible blindness. Due to its slow progression, 50% of patients in the developed world and 90% in the developing world are untreated. While Glaucoma is currently incurable, with early detection and treatment, its progression can be halted.
Posted on February 6, 2015 by Noah Nemoy
The past year has been one of tremendous growth and new opportunities for both MEMOTEXT – one of the pioneering mHealth companies – and mHealth as a whole. The two trends that power the mHealth revolution; increased usage of mobile technology and the move towards decentralized and personalized health care, have continued unabated. While mHealth is an industry still largely in its infancy, the use of this technology will only increase as the gap between the 10% of smartphone owners using health apps and 72% of patients using mobile apps, continues to close.